Momenta Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2006
Posted on: Thursday, 31 August 2006, 09:00 CDT
CAMBRIDGE, Mass., Aug. 31 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. , a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that Steven B. Brugger, Senior Vice President, Strategic Business Operations, will present at the Thomas Weisel Partners Healthcare Conference 2006 on Wednesday, September 6, 2006 at 3:50 pm EDT at The Four Seasons Hotel, Boston, MA. A live audio webcast of the presentation will be available on the "Investors" section of the Company's website located at http://www.momentapharma.com/. A replay of the presentation will be posted on the Momenta website approximately thirty minutes after the event and will be available through October 6, 2006.
About Momenta:
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed characterization and engineering of complex sugars. Momenta is applying its technology to create technology-enabled generic versions of sugar-based and other complex drug products, develop improved versions of existing drugs, and discover novel drugs and new biological processes. The Company's most advanced product candidate is M-Enoxaparin, a technology- enabled generic version of Lovenox(R). Momenta's first improved drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. The Company is developing other novel drug candidates through its discovery effort focused on understanding sugar-based biological processes. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit our website at http://www.momentapharma.com/, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Michael A. Lawless Momenta Pharmaceuticals, Inc. 617-395-5189
Momenta Pharmaceuticals, Inc.
CONTACT: Michael A. Lawless, Momenta Pharmaceuticals, Inc.,+1-617-395-5189
Web site: http://www.momentapharma.com/
Source: PRNewswire-FirstCall
Related Articles
- Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Fourth Quarter 2006 Financial Results
- Momenta Pharmaceuticals to Present at BIO Investor Forum 2006
- Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Third Quarter 2006 Financial Results
- Momenta Pharmaceuticals to Present at the Bank of America 2006 Specialty Pharmaceuticals Conference
- Momenta Pharmaceuticals Files Investigational New Drug Application for Novel Anticoagulant for Acute Coronary Syndromes
- Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Second Quarter 2006 Financial Results
- Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for First Quarter 2006 Financial Results
- Momenta Pharmaceuticals to Present at the Deutsche Bank 2006 Heath Care Conference
- Momenta Pharmaceuticals Announces Abbreviated New Drug Application Filing for M-Enoxaparin
 |
 |
User Comments (0)
RSS Feeds